Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
107 Cards in this Set
- Front
- Back
What happens at phase 0 of the cardiac myocyte?
|
Upstroke: Na channels open (+70 mV), Na influx
|
|
What happens at phase 1 of the cardiac myocyte?
|
Early-fast repolarization: Na channels close, Ca, K channels open
|
|
What happens at phase 2 of the cardiac myocyte?
|
Plateau: Ca channels dominate (ECa = 119 mV), more K channels begin to open.
|
|
What happens at phase 3 of the cardiac myocyte?
|
Repolarization: K channels dominate EK = -88 mV
|
|
What happens at phase 4 of the cardiac myocyte?
|
Diastole: steady state equilibrium between pump activity and Ca influx. Usually see a slow depolarization
|
|
What does verapamil do to phase 4 of the SA node action potential?
|
It decreases the slope
|
|
What are the three mechanisms by which arrhythmias occur?
|
1. Abnormal impulse initiation
- Increases automaticity, ectopic focus 2. Abnormal impulse conduction - Microscopic reentry - Macroscopic reentry 3. Some combination of the above - "R on T" phenomenon - Early and delayed after depolarizations? |
|
What would you see on EKG in a patient with ectopic atrial tachycardia (EAT)?
|
Unusual P-wave morphology in lead II. Tachycardia (~150 bpm)
|
|
In what case would EAT trump the SA node action potential?
|
If the phase 4 depolarization of the EAT were faster than the SA node depolarization.
|
|
What do all of these have in common?
Digoxin Adrenergic agonists Anticholinergics |
They all can contribute to increased automaticity
|
|
What are some examples of diseases that can cause arrhythmias via irritation?
|
Pericarditis
Stretching (increased pressure) Lung disease, pneumonia |
|
Bidirectional tachycardia (~150): diagnosis?
|
Digoxin toxicity
|
|
P-waves of at least three different morphologies + tachycardia = ?
|
MAT (multifocal atrial tachycardia)
|
|
If reentrant arrhythmias require "perfect timing," what is the general strategy of the treatment?
|
Screw up the timing.
|
|
Wolf-Parkinson-White
|
Results from an accessory bypass track (bundle of Kent)
Will see "delta" waves on EKG, indicating ventricular pre-excitation. These can be seen as a part of the R wave upstroke. Will also see widening of the R wave. Mostly asymptomatic, but can cause sudden death. |
|
"R on T" phenomenon
|
QRS of PVC falls on sinus T wave and starts a run of V tach.
|
|
"Torsades de Pointes": lethal or non-lethal?
|
Lethal
|
|
What would you see on EKG in a patient with ectopic atrial tachycardia (EAT)?
|
Unusual P-wave morphology in lead II. Tachycardia (~150 bpm)
|
|
In what case would EAT trump the SA node action potential?
|
If the phase 4 depolarization of the EAT were faster than the SA node depolarization.
|
|
What do all of these have in common?
Digoxin Adrenergic agonists Anticholinergics |
They all can contribute to increased automaticity
|
|
What are some examples of diseases that can cause arrhythmias via irritation?
|
Pericarditis
Stretching (increased pressure) Lung disease, pneumonia |
|
Bidirectional tachycardia (~150): diagnosis?
|
Digoxin toxicity
|
|
P-waves of at least three different morphologies + tachycardia = ?
|
MAT (multifocal atrial tachycardia)
|
|
If reentrant arrhythmias require "perfect timing," what is the general strategy of the treatment?
|
Screw up the timing.
|
|
Wolf-Parkinson-White
|
Results from an accessory bypass track (bundle of Kent)
Will see "delta" waves on EKG, indicating ventricular pre-excitation. These can be seen as a part of the R wave upstroke. Will also see widening of the R wave. Mostly asymptomatic, but can cause sudden death. |
|
"R on T" phenomenon
|
QRS of PVC falls on sinus T wave and starts a run of V tach.
|
|
"Torsades de Pointes": lethal or non-lethal?
|
Lethal
|
|
Ventricular tachycardia, Ventricular fibrillation = ?
|
Death
|
|
General philosophy about treating arrhythmias?
|
"When it's slow, make it fast. When it's fast, make it slow."
|
|
Class I antiarrhythmics: M of A
|
Na channel blockers.
Raise the action potential threshold, so phase 4 is lengthened --> dec in automaticity |
|
Quinidine: general
|
Class IA antiarrhythmic
Not first line b/c of Afib associated mortality |
|
Quinidine: dosing
|
Loading dose, then 2-3 times daily
No IV |
|
Quinidine: AE
|
Prolongs QT interval (K blockade) --> predisposing to Torsade de Pointes
Diarrhea, tinnitus, visual changes Can be pro-arrhythmic Increases levels of digoxin |
|
Quinidine: drug interactions
|
Increases levels of digoxin (often used together)
|
|
Procainamide: class
|
Class IA antiarrhythmic
|
|
Procainamide: route
|
PO or IV
|
|
Procainamide: metabolism
|
Hepatic: PCA --> NAPA --> elimination
|
|
Procainamide: AE
|
Prolongs QT (NAPA is a potent K blocker)
Agranulocytosis (0.01%) Drug induced lupus (slow acetylators) Pro-arrhythmic |
|
Procainamide: what population of people have high levels of metabolites?
|
Fast acetylators will have increased NAPA levels and therefore be at more of a risk for prolonged QT
|
|
Disopyramide: class
|
Class IA antiarrhythmic
|
|
Disopyramide: route
|
PO only
|
|
Disopyramide: AE
|
Prolongs QT
Major AE is negative inotropy: - Not helpful in patients with CHF - Useful in patients with hypertrophic cardiomyopathy (too much ventricular function) - Also anticholinergic (causes vasoconstriction, makes CHF worse) |
|
Disopyramide: drug interactions
|
Phenobarbital, phenytoin increase the hepatic metabolism of disopyramide.
|
|
Name the three class IA antiarrhythmics
|
Procainamide
Quinidine Disopyramide |
|
Class IA antiarrhythmics: Uses
|
Afib, Aflutter, SVT, VT
|
|
Class IA antiarrhythmics: general effects on the action potential
|
- Decrease conduction velocity
- Change the refractory period (K blockade) |
|
Lidocaine: route
|
Given as an IV load followed by an infusion.
|
|
Lidocaine: especially useful with what?
|
MI. Lidocaine blocks depolarized (sick) cells better.
|
|
Lidocaine: shortcomings
|
Vd and clearance decreased in CHF
Clearance falls after 24 hrs. |
|
Lidocaine: AE
|
CNS toxicity:
Tremor, slurred speech, metallic taste, seizures |
|
Lidocaine: M of A
|
Voltage-dependant Na blocker. Blocks rhythms made by the ischemic heart.
|
|
Lidocaine: drug interactions
|
Watch out for use with CHF patients and with administration of cimetidine (H2 histamine blocker)
|
|
Flecainide: class
|
Class IC antiarrhythmic
|
|
Flecainide: route
|
PO only
|
|
Flecainide: use
|
Primarily for SVT:
- Suppresses PVCs - But it kills people with a history of MI and PVCs. |
|
Flecainide: half-life
|
Long (20 hrs)
|
|
Use dependence: definition
|
Drug binds to the transient form of the channel in its active or inactive state.
Works better with faster heart rates |
|
Reverse use dependence: definition
|
Binds to the resting (more durable) form of the channel.
Works better with slower heart rates. |
|
Propafenone: class
|
Class IC antiarrhythmic
|
|
Propafenone: dosing, half-life
|
Short half-life, requires 2-3x daily dosing
|
|
Propafenone: beta blocking activity
|
1/40 of that of propranolol
|
|
Propafenone: AE
|
Hypersensitivity reactions, lupus-like syndromes, agranulocytopenia, CNS disturbances: dizziness, lightheadedness, GI upset, metallic taste, bronchospasm
|
|
Class IC antiarrhythmics: major contraindication
|
CAD
|
|
QT prolongation predisposes to what
|
Torsades de Pointes
|
|
Class II Antiarrhythmics: alternate name?
|
Beta blockers
|
|
Class II Antiarrhythmics: M of A
|
Decrease the phase 4 depol rate (this phase is sensative to adrenergic tone). This reduces cardiac automaticity.
|
|
Class II Antiarrhythmics: Effects on the heart
|
Reduces the pacemaker rate, decreases AV conduction, increases AV refractoriness.
|
|
Class II Antiarrhythmics: effects on mortality
|
Decrease mortality with MI
|
|
Class II Antiarrhythmics: AE
|
Bronchospasm, bradycardia, depression (due to lipid solubility of some beta blockers)
|
|
Class II Antiarrhythmics: dosing
|
once or twice daily
|
|
Class III Antiarrhythmics: M of A
|
Delayed repolarization via K channel blockade.
Extends phase 3. Amiodarone also decreases conduction velocity and phase 4 depolarization. |
|
Amiodarone: class
|
Class III Antiarrhythmic
"Amiodarone is the most effective antiarrhythmic" |
|
Amiodarone: what does it do?
|
Slows HR and AV node conduction.
Inhibits manny channel types: K (IKr) Na (inactive) Ca (weak) Beta-adrenergic receptors (weak) |
|
Amiodarone: route
|
Available PO or IV. IV administration causes hypotension
|
|
Amiodarone: drug interactions
|
Competes with carrier proteins:
Increases digoxin concentrations Increases warfarin concentrations Also: quinidine, procainamide, flecainide, beta-blockers, CCBs, mexiletine |
|
Amiodarone: pharmacokinetics
|
HUGE Vd (resides in lipid stores). So if you put someone on amiodarone for 1 year, it will be stored up in the body for a long time...
Very long half-life Hard to get rid of |
|
Amiodarone: AE
|
FATAL pulmonary fibrosis (1%)
Skin: photosensitivity, blue-man syndrome Eye: Corneal deposits GI: increased LFTs Endo: Blocks T4 to T3 conversion Lots of drug interactions |
|
Dofetilide: class
|
Class III Antiarrhythmic
|
|
Dofetilide: route
|
Only PO
|
|
Dofetilide: use
|
Only for atrial arrhythmias.
|
|
Dofetilide: AE
|
HIGH incidence of Torsades de Points. Thus initiation of dofetilide requires hospitalization and trained physician.
|
|
Dofetilide: M of A
|
Pure K channel blocker
Class III Anti-arrhythmic |
|
Dofetilide: clearance
|
80% renal clearance (keep an eye on Cr clearance)
|
|
Dofetilide: drug interactions
|
Agents that interfere with renal cation exchange should be avoided:
Verapamil, cimetidine, hydrochlorothiazide, itraconazole, ketoconazole, prochlorperazine, and trimethoprim. |
|
Sotalol: class
|
Class III Antiarrhythmic
|
|
Sotalol: what is it, route
|
Class III Antiarrhythmic
PO only |
|
Sotalol: use/activity
|
Class III Antiarrhythmic
Has beta-blocking activity (L-enantiomer) Used for ventricular tachycardia |
|
Sotalol: AE
|
Class III Antiarrhythmic
Moderate incidence of Torsades de Pointes Use with caution in CHF |
|
Which class of antiarrhythmics requires the most caution?
|
Class III (amiodarone toka)
|
|
Class IV antiarrhythmics: M of A
|
Block the slow inward Ca current of phase 4 --> slow heart rate.
Also slow AV node repolarization |
|
Class IV antiarrhythmics: generally used for, not used for?
|
Used to slow HR and inhibit reentry
Not used for ventricular arrhythmias. |
|
Class IV antiarrhythmics: alternate name?
|
Calcium channel blockers.
|
|
Class IV antiarrhythmics: elimination?
|
Hepatic
|
|
Class IV antiarrhythmics: AE
|
Hypotension due to smooth muscle relaxation
Constipation |
|
Class IV antiarrhythmics: drug interactions
|
Digoxin levels may increase
Theophylline levels increase |
|
Digoxin: General M of A
|
Effects mediated via central and peripheral augmentation of vagal tone.
|
|
Digoxin: AE
|
Anorexia, nausea, vomiting, changes in color vision (Van Gogh), arrhythmias (bidirectional VT)
|
|
Adenosine: what does it do?
|
AV nodal blockade.
|
|
Adenosine: what types of patients are highly sensitive?
|
Heart transplant patients - they are denervated.
|
|
Adenosine: what can adenosine help you figure out about arrhythmias?
|
It can help you figure out if it is coming from the atria or the ventricles b/c it causes a AV nodal blockade.
|
|
Adenosine: AE
|
Chest pain and dyspnea (short-lived)
Proarrhythmic: decreased atrial refractoriness can lead to Afib. |
|
Adenosine: half-life
|
Short
|
|
Atropine: what type of drug
|
Muscarinic antagonist
|
|
Atropine: use for CV
|
Used for bradyarrhythmias
|
|
Atropine: route
|
IV only
|
|
Atropine: not effective in treating arrhythmias if?
|
If the block is below the AV node.
|
|
Amiodarone toxicity can present like what?
|
Like pneumonia
|